Patents Assigned to Pfizer Inc.
  • Boron Containing PDE4 Inhibitors
    Publication number: 20230148402
    Abstract: The present invention relates to boron containing compounds of Formula (I) X—Y—Z ??Formula (I) that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.
    Type: Application
    Filed: December 15, 2022
    Publication date: May 11, 2023
    Applicant: Pfizer Inc.
    Inventors: Tsutomu Akama, David Clive Blakemore, Robert Toms Jacobs, Peter Jones, David Christopher Limburg, Martins Sunday Oderinde, Matthew Alexander Perry, Jacob John Plattner, Joseph Walter Strohbach, Rubben Federico Torella, Thean Yeow Yeoh, Yasheen Zhou
  • Melanocortin 4 receptor antagonists and uses thereof
    Patent number: 11643412
    Abstract: Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: May 9, 2023
    Assignee: Pfizer Inc.
    Inventors: Christopher Ryan Butler, Michelle Renee Garnsey, Kevin Alexander Ogilvie, Jana Polivkova, Matthew Forrest Sammons, Aaron Christopher Smith, Qingyi Yang
  • Method Of Preparing A Therapeutic Protein Formulation And Antibody Formulation Produced By Such A Method
    Publication number: 20230134160
    Abstract: The invention relates to a method of preparing a protein formulation including a therapeutic protein, the method comprising the steps of: providing a solution comprising said protein; concentrating the protein in the solution by a first ultra-filtration step; diafiltering the solution with a diafiltration buffer including at least one first excipient, whereby a retentate is obtained comprising the protein and the first excipient; further concentrating the protein in the retentate by a second ultra-filtration step; and adding at least one final excipient, whereby the protein formulation with a desired protein concentration is obtained. According to the inven tion, the method further comprises, before the second ultra-filtration step, adding a second excipient to the retentate obtained from the diafiltration step. The invention is also directed to antibody formulations produced by the foregoing method.
    Type: Application
    Filed: September 8, 2016
    Publication date: May 4, 2023
    Applicant: PFIZER INC.
    Inventors: Judy Kay GLYNN, Brian Xin CHEN, Daniel Patrick LACASSE
  • Pharmaceutical compounds
    Patent number: 11634425
    Abstract: Benzodiazepine derivatives of formula (I): (I) wherein: each of R1 and R2 is independently H or halo; either (i) T is N, Z is C, -a- and -c- are bonds, and -b- and -d- are absent; or (ii) T is C, Z is N, -b- and -d- are bonds, and -a- and -c- are absent; each of R3 and R4 is independently halo, —OR6, —NR6R7—COR8, —C(O)OR8, —CON(R8)2 or —R6; R5 is H or halo; each of R6 and R7 is independently H or a group selected from C1-C6 alkyl, C3-C10 cycloalkyl, C6-C10 aryl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, the group being unsubstituted or substituted; R8 is H or C1-C6 alkyl, each R8 being the same or different when two are present; n is 0 or 1; and one of V, W, X and Y is N or CH and the other three are CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.
    Type: Grant
    Filed: June 21, 2022
    Date of Patent: April 25, 2023
    Assignee: PFIZER INC.
    Inventors: George Stuart Cockerill, James Good, Edward James Cochrane
  • Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
    Patent number: 11634410
    Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: April 25, 2023
    Assignee: Pfizer Inc.
    Inventors: Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
  • Tissue factor pathway inhibitor antibodies and uses thereof
    Patent number: 11634504
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: April 25, 2023
    Assignee: Pfizer Inc.
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • Compounds and Method of Treating COVID-19
    Publication number: 20230120707
    Abstract: The invention relates to compounds of formula I wherein R1 and R2 are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compound
    Type: Application
    Filed: March 31, 2021
    Publication date: April 20, 2023
    Applicant: Pfizer Inc.
    Inventors: Robert Steven Kania, Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Forrest Sammons, Jamison Bryce Tuttle
  • GLP-1 RECEPTOR AGONISTS AND USES THEREOF
    Publication number: 20230124938
    Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Application
    Filed: October 24, 2022
    Publication date: April 20, 2023
    Applicant: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, David Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
  • COMBINATION OF AN ANAPLASTIC LYMPHOMA KINASE INHIBITOR AND A CYCLIN DEPENDENT KINASE INHIBITOR
    Publication number: 20230117684
    Abstract: This invention relates to combination therapies comprising an inhibitor of anaplastic lymphoma kinase (ALK) and, an inhibitor of cyclin dependent kinase 4 and 6 (CDK4/6 inhibitor) or an inhibitor of cyclin dependent kinase 2, 4 and 6 (CDK2/4/6 inhibitor), and associated methods of treatment, combinations, pharmaceutical compositions and uses thereof.
    Type: Application
    Filed: March 2, 2021
    Publication date: April 20, 2023
    Applicant: Pfizer Inc.
    Inventors: Ping Wei, Scott Lawrence Weinrich
  • Nitrile-Containing Antiviral Compounds
    Publication number: 20230120254
    Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
    Type: Application
    Filed: September 14, 2022
    Publication date: April 20, 2023
    Applicant: Pfizer Inc.
    Inventors: Dafydd Rhys Owen, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Qingyi Yang
  • 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS
    Publication number: 20230120188
    Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.
    Type: Application
    Filed: December 1, 2022
    Publication date: April 20, 2023
    Applicant: Pfizer Inc.
    Inventors: Shelley ALLEN, Patrick Michael DOERNER BARBOUR, James Francis BLAKE, Sydney Taylor BLANCHE, Mark Laurence BOYS, Wesley Dewitt CLARK, Connor James COWDREY, Joshua Ryan DAHLKE, Alex Andrew KELLUM, Ellen Margaret KNAPP, David Austin MORENO, Jacob Matthew O'LEARY, Li REN, Faith Elizabeth WITKOS
  • Human cytomegalovirus gB polypeptide
    Patent number: 11629172
    Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: April 18, 2023
    Assignee: Pfizer Inc.
    Inventors: Philip Ralph Dormitzer, Ye Che, Xiaoyuan Sherry Chi, Seungil Han, Kyle Paul Heim, Thomas Richard Jones, Yuhang Liu, Xiayang Qiu, Xinzhen Yang, Xiaojie Yao, Matthew Curtis Griffor, Jennifer Anne Nicki
  • Method of Treating COVID-19
    Publication number: 20230105838
    Abstract: The invention relates to methods of treating COVID-19 in a patient by administering therapeutically effective amounts of certain SARS-CoV-2 inhibitor compounds or pharmaceutical compositions containing them to a patient in need thereof. The invention also relates to inhibiting SARS-CoV-2 coronavirus viral replication activity comprising contacting SARS-CoV-2-related coronavirus protease with a therapeutically effective amount of a SARS-Cov-2 protease inhibitor, such as a SARS-Cov-2 3CL protease inhibitor and compositions comprising the same.
    Type: Application
    Filed: April 1, 2021
    Publication date: April 6, 2023
    Applicant: Pfizer Inc.
    Inventors: Robert Louis Hoffman, Robert Steven Kania, Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Forrest Sammons, Jamison Bryce Tuttle
  • Antibodies and antibody-drug conjugates specific for CD123 and uses thereof
    Patent number: 11613581
    Abstract: The present invention provides antibodies that specifically bind to CD123. The invention further relates to immunoconjugates (e.g., antibody-drug conjugates, or ADCs) comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and ADCs for the treatment of a condition associated with cells expressing CD123 (e.g., cancer or autoimmune disease).
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: March 28, 2023
    Assignee: Pfizer, Inc.
    Inventors: Manoj Baburao Charati, Yoon-Chi Han, Madan Katragadda, Nicole Melissa Piché-Nicholas, Lawrence Nathan Tumey
  • Antibody-drug conjugates with high drug loading
    Patent number: 11602525
    Abstract: The present invention provides transglutaminase-mediated antibody-drug conjugates with high anti-body-drug ratio (DAR) comprising 1) glutamine-containing tags, endogenous glutamines, and/or endogenous glutamines made reactive by antibody engineering or an engineered transglutaminase (e.g., with altered substrate specifity); and 2) amine donor agents comprising amine donor units, linkers, and agent moieties, wherein the DAR is at least about 5. The invention also provides methods of making and methods of using such higher drug loaded antibody-drug conjugates.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: March 14, 2023
    Assignees: RINAT NEUROSCIENCE CORP., PFIZER INC.
    Inventors: Pavel Strop, Katherine Anne Delaria, Magdalena Dorywalska, Davide Luciano Foletti, Russell George Dushin, David Louis Shelton, Arvind Rajpal
  • Glycoconjugation process
    Patent number: 11603384
    Abstract: The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: March 14, 2023
    Assignee: Pfizer Inc.
    Inventors: Mingming Han, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad
  • Anti-E-selectin antibodies, compositions and methods of use
    Patent number: 11597770
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to E-selectin. The invention includes uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: March 7, 2023
    Assignee: Pfizer Inc.
    Inventors: James Reasoner Apgar, Sheryl Rubio Bowley, Joanne Elizabeth-Ayriss Elwell, Laura Lin, Jatin Narula, Chuenlei Parng, Debra Denene Pittman, Swapnil Rakhe, Chihyi Vincent Yu
  • COMBINATION THERAPIES USING CDK INHIBITORS
    Publication number: 20230053328
    Abstract: This invention relates to a method for treating cancer by administering a CDK4/6 inhibitor or CDK2/4/6 inhibitor in combination with a 4-1BB agonist and/or an OX40 agonist to a subject in need thereof.
    Type: Application
    Filed: May 21, 2020
    Publication date: February 16, 2023
    Applicant: Pfizer Inc.
    Inventors: Stephen George Dann, Cecilia Marianne Oderup, Shahram Salek-Ardakani
  • Humanized antibodies
    Patent number: 11578428
    Abstract: Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: February 14, 2023
    Assignee: Pfizer Inc.
    Inventors: William James Jonathan Finlay, Lioudmila Tchistiakova, Eric M. Bennett
  • Solid Forms of 2-((4-((S)-2-(5-Chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt
    Publication number: 20230045419
    Abstract: The invention provides solid forms of 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt for example, a hydrate (e.g. a monohydrate) crystalline form (e.g. Form 2 or Form 3) or an amorphous form; as well as pharmaceutical compositions, and the uses thereof in treating diseases, conditions or disorders modulated by GLP-1R in a mammal, such as a human.
    Type: Application
    Filed: December 7, 2020
    Publication date: February 9, 2023
    Applicant: Pfizer Inc.
    Inventors: Gary E. Aspnes, Scott W. Bagley, Wesley Dewitt Clark, John M. Curto, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David Andrew Griffith, Kim Huard, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David Walter Piotrowski, Roger B. Ruggeri